Abstract
Hyperlipidemia is a common cardiovascular disease characterized by elevated lipid level in association with disordered lipoproteins metabolism. Atorvastatin, an HMG-CoA reductase inhibitor, has been developed as an antihyperlipidaemic agent and proved to exhibit antioxidant activity against lipid peroxidation. The two hydroxyl metabolites of atorvastatin, Ortho-hydroxy-atorvastatin and para-hydroxy-atorvastatin, are equipotent to their parent compound. Anethol trithione is a kind of liver protecting agent used to treat the hepatobiliary disease-related symptoms. Desmethyl anethol trithione, the degradation product of anethol trithione, keeps the related activity of anethol trithione and it is suitable for developing novel prodrugs. In this letter, a series of atorvastatin derivatives was designed as lipid regulators based on the structures of para-hydroxy-atorvastatin and desmethyl anethol trithione. Preliminary biological evaluation suggested compound 11a presented promising antihyperlipidemic, antioxidant activity and plasma stability.
Keywords: Hyperlipidemia, Atorvastatin derivatives, Anethol trithione, Antihyperlipidaemic activity, Antioxidant activity, Plasma stability.
Letters in Drug Design & Discovery
Title:Synthesis and Biological Evaluation of Atorvastatin Derivatives as Novel HMG-CoA Reductase Inhibitors
Volume: 10 Issue: 9
Author(s): Jiayi Tong, Naxin Wang and Hua Xiao
Affiliation:
Keywords: Hyperlipidemia, Atorvastatin derivatives, Anethol trithione, Antihyperlipidaemic activity, Antioxidant activity, Plasma stability.
Abstract: Hyperlipidemia is a common cardiovascular disease characterized by elevated lipid level in association with disordered lipoproteins metabolism. Atorvastatin, an HMG-CoA reductase inhibitor, has been developed as an antihyperlipidaemic agent and proved to exhibit antioxidant activity against lipid peroxidation. The two hydroxyl metabolites of atorvastatin, Ortho-hydroxy-atorvastatin and para-hydroxy-atorvastatin, are equipotent to their parent compound. Anethol trithione is a kind of liver protecting agent used to treat the hepatobiliary disease-related symptoms. Desmethyl anethol trithione, the degradation product of anethol trithione, keeps the related activity of anethol trithione and it is suitable for developing novel prodrugs. In this letter, a series of atorvastatin derivatives was designed as lipid regulators based on the structures of para-hydroxy-atorvastatin and desmethyl anethol trithione. Preliminary biological evaluation suggested compound 11a presented promising antihyperlipidemic, antioxidant activity and plasma stability.
Export Options
About this article
Cite this article as:
Tong Jiayi, Wang Naxin and Xiao Hua, Synthesis and Biological Evaluation of Atorvastatin Derivatives as Novel HMG-CoA Reductase Inhibitors, Letters in Drug Design & Discovery 2013; 10 (9) . https://dx.doi.org/10.2174/15701808113106660020
DOI https://dx.doi.org/10.2174/15701808113106660020 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Toll-Like Receptors: Link between “Danger” Ligands and Plaque Instability
Current Drug Targets Sleep Related Disorders in the Elderly: An Overview
Current Respiratory Medicine Reviews Impact of High Protein Intake on Viral Load and Hematological Parameters in HIV-infected Patients
Current HIV Research Hyperhomocysteinemia in Movement Disorders: Current Evidence and Hypotheses
Current Vascular Pharmacology Vaccine Adjuvants: Key Tools for Innovative Vaccine Design
Current Topics in Medicinal Chemistry Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis
Current Pharmaceutical Design Treatment of Leukoaraiosis: A Futuristic View
Current Drug Targets Therapies Targeting Innate Immunity for Fighting Inflammation in Atherosclerosis
Current Pharmaceutical Design Phytogenic Polyphenols as Glycogen Phosphorylase Inhibitors: The Potential of Triterpenes and Flavonoids for Glycaemic Control in Type 2 Diabetes
Current Medicinal Chemistry Targeting Molecular Imaging Approach for Detection of Infection and Inflammation by Diagnostic Nuclear Medicine Techniques
Current Medical Imaging Synthesis, Characterization and Physico-chemical Properties of New 2-(4- Arylpiperazine-1-yl)-1-(3-methylbenzofuran-2-yl)ethanoles as Potential Antihypertensive Agents
Current Organic Chemistry Influence of Physical Immobilization of dsDNA on Carbon Based Matrices of Electrochemical Sensors
Current Pharmaceutical Analysis Drugs Designed to Improve Endothelial Function: Effects on Erectile Dysfunction
Current Pharmaceutical Design Echocardiographic Hemodynamic Monitoring in the Critically Ill Patient
Current Cardiology Reviews Alzheimer's Disease and Diabetes: New Insights and Unifying Therapies
Current Diabetes Reviews The Framingham Brain Donation Program: Neuropathology Along the Cognitive Continuum
Current Alzheimer Research Chymase Inhibitor As a Novel Therapeutic Strategy for Anti-Vascular Remodeling
Vascular Disease Prevention (Discontinued) The Role of Autophagy in the Pathogenesis of Ischemic Stroke
Current Neuropharmacology Impact of Polypharmacy on Adherence to Evidence-Based Medication in Patients who Underwent Percutaneous Coronary Intervention
Current Vascular Pharmacology Therapeutic Utilities of Pediatric Cardiac Catheterization
Current Cardiology Reviews